Last reviewed · How we verify
Zyloprim® 300 mg
At a glance
| Generic name | Zyloprim® 300 mg |
|---|---|
| Sponsor | Ardea Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
- Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence. (PHASE1)
- T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer (PHASE1)
- IVIVR Assessing PK Parameters Used to Establish Bioequivalence (PHASE1)
- Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zyloprim® 300 mg CI brief — competitive landscape report
- Zyloprim® 300 mg updates RSS · CI watch RSS
- Ardea Biosciences, Inc. portfolio CI